Investigators detected more than 100 risk loci for primary open-angle glaucoma, with mostly similar effects in people with European, Asian, or African ancestry.
Initial partners in the program include Thermo Fisher Scientific, GNS Healthcare, DNAnexus, Personal Genome Diagnostics, and the Wellcome Sanger Institute.
A new study lends credence to the idea that pre-existing anti-cancer immunity depends heavily on patients' genetic background, according to one of the researchers.
